Last Week in Biomedicine | May 30 – Jun 5 | Part 2 of 2: Talzenna Prostate Combo, IgG4 Disease First

From a prostate cancer combo that uses your tumor's own broken DNA-repair against it, to the first drug ever to succeed in a rare autoimmune disease called IgG4-related disease — Part 2 of our weekly biomedicine recap covers three more major readouts from the week of May 30 – June 5, 2026. In Part 2 we cover:

4. Pfizer — Talazoparib plus enzalutamide for metastatic castration-sensitive prostate cancer with DNA-repair mutations (Phase 3)

5. Zenas BioPharma — Obexelimab for IgG4-related disease (Phase 3)

6. Karyopharm Therapeutics — Selinexor plus ruxolitinib for myelofibrosis (Phase 3)

The IgG4-RD result may be the most quietly historic of the week: IgG4-related disease is a rare autoimmune condition where misbehaving B cells form fibrotic masses in organs throughout the body, and there has never been an approved therapy — patients rely on steroids long-term. Obexelimab, a clever 'bifunctional' antibody that calms B cells without killing them, cut the risk of disease flare by 56% in a 52-week Phase 3 trial — the first positive Phase 3 ever in this disease, published in the New England Journal of Medicine. We explain what makes the antibody design unusual and why a positive trial here could change rare-disease drug development more broadly.

Catch Part 1 if you missed it. Subscribe at TrialBreaks.com

#oncology #prostatecancer #PARPinhibitor #autoimmune #IgG4 #rheumatology #rarediseases #myelofibrosis #hematology #targetedtherapy #precisionmedicine #biomedicine #clinicaltrials #science

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(13)

Last Week in Biomedicine | June 14–20 | Part 2 of 2: Mezigdomide Myeloma, HCM Heart Drug

Part 2 of our week of June 14–20, 2026 wrap-up covers a new molecular glue for relapsed multiple myeloma that cut disease progression by half, a heart drug that may finally work forboth forms of hyper...

25 Kesä 25min

Last Week in Biomedicine | June 14–20 | Part 1 of 2: CRISPR HAE Cure, Narcolepsy Orexin Breakthrough

This week opened with one of the most significant gene-editing milestones in clinical medicine: a single CRISPR infusion cut hereditary angioedema attacks by 87 percent in a Phase 3 trial, published t...

23 Kesä 34min

Last Week in Biomedicine | June 6–13 | Part 2 of 2: CagriSema Diabetes, Sickle Cell Plenary

Part 2 of our June 6–13 wrap-up: Novo Nordisk's CagriSema beats semaglutide alone in three Phase 3 diabetes trials, Takeda's zasocitinib pill outperforms Sotyktu head-to-head in psoriasis, and Agios's...

18 Kesä 21min

Last Week in Biomedicine | June 6–13 | Part 1 of 2: Retatrutide Weight Loss, Weekly HIV Pill

A blockbuster week in biomedicine — Eli Lilly's retatrutide produced weight loss approaching bariatric surgery in Phase 3, and Gilead and Merck's once-weekly oral HIV pill cleared two Phase 3 trials. ...

16 Kesä 20min

Last Week in Biomedicine | May 30 – Jun 5 | Part 1 of 2: Daraxonrasib Pancreatic Cancer, Ivonescimab Lung

The biggest week in cancer research of 2026 dropped at the ASCO meeting in Chicago, and one drug stole the show: a new RAS-blocking pill that nearly doubled survival in metastatic pancreatic cancer, o...

9 Kesä 20min

Last Week in Biomedicine | May 23–29 | Part 2 of 2: Apogee Eczema, TG Therapeutics MS

In Part 2 we cover the remaining clinical trial readouts from the week of May 23–29, 2026 — a Phase 2 atopic dermatitis breakthrough and a Phase 3 multiple sclerosis convenience win.4. Apogee Therapeu...

4 Kesä 11min

Last Week in Biomedicine | May 23–29 | Part 1 of 2: BMS Myeloma, GSK Hep B Cure, Pfizer Lung Cancer

In Part 1 we cover the three biggest clinical trial readouts from the week of May 23–29, 2026 — including two ASCO 2026 opening-day announcements that reshape oncology.1. Bristol Myers Squibb — Mezigd...

2 Kesä 36min